A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Clinical trial NCT05514054 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05514054
Sponsor: Eli Lilly and Company
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Neoplasms

Start date: 2022-10-04
Primary completion: 2027-10-01
Enrollment: 8000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.